Ecovia Bio, a Michigan-based biotechnology company focused on sustainable biopolymer ingredients, said it has closed a Series B funding round led by Pointe Angels, an angel investor group based in the Grosse Pointe communities east of Detroit.
The company said the new capital will support a major expansion of manufacturing capacity at its Livonia facility as it scales production of its AzuraBase and AzuraGel product families, which are based on gamma polyglutamic acid (γ-PGA) and related specialty biopolymers. Ecovia Bio positions γ-PGA as a biodegradable alternative to petrochemical-derived superabsorbent polymers used across applications, including cosmetics and personal care, agriculture, and hygiene products.
Ecovia Bio said the expansion is intended to meet what it described as rising global demand for bio-based ingredients that can replace persistent synthetic polymers and help brands respond to regulatory scrutiny and consumer expectations around product safety and sustainability. The company also said it has started evaluating additional production facilities to support demand beyond its current capacity plans and to strengthen long-term supply security for customers.
As part of the planned buildout, Ecovia Bio expects the Livonia site to reach full operational capacity by 2028, creating a platform to serve multiple end markets from an optimized manufacturing footprint.
Ecovia Bio is a University of Michigan spinout that commercializes fermentation-derived biopolymers, with γ-PGA as its lead technology, according to the announcement. Pointe Angels, founded in 2019, said it provides accredited investors access to early-stage venture opportunities and takes a hands-on approach across functional areas including operations, engineering, and manufacturing.
KEY QUOTES
“We are excited to partner with Pointe Angels. This capital enables us to meet immediate demand from our cosmetics, personal care, and agricultural customers while establishing the infrastructure needed to serve the hygiene sector at industrial scale.”
Kousay Said, Chief Executive Officer, Ecovia Bio
“Ecovia Bio represents exactly the kind of venture we love to back at Pointe Angels. The company has solved a real technical challenge—producing sustainable, high-performance γ-PGA at commercial scale—and now has the market traction to justify expansion. What impressed us most was the management team’s disciplined approach to capacity planning and their ability to serve multiple end markets from a single, optimized manufacturing platform. We’re confident this capital will unlock significant value for our investors while strengthening Michigan’s position as a leader in biotechnology and advanced manufacturing.”
David Bloom, Executive Director, Pointe Angels
